For research and informational purposes only
Clinical studies have demonstrated that retatrutide can reduce markers of inflammation, such as C-reactive protein (CRP), which are associated with an increased risk of cardiovascular events
The challenge here is that environmental conditions influencing responses ( Figure 1 ) should either be kept identical for all treatments or at least be examined statistically for example using multiparametric analysis (Serdobolskii, 2018)
Please ask your prescriber or pharmacist if you are not entirely sure
Our doctors emphasise that monitoring and open communication reduce risks: regular follow-up, blood tests for glucose and kidney function, and reporting worrying symptoms promptly
Choi, H., Jo, G., Yang, J